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Background. Serology is the mainstay for syphilis diagnosis and treatment monitoring. We investigated sero-
logical response to treatment of syphilis according to disease stage and HIV status.
Methods. A retrospective cohort study of 264 patients with syphilis was conducted, including 90 primary, 133
secondary, 33 latent, and 8 tertiary syphilis cases. Response to treatment as measured by the Venereal Disease
Research Laboratory (VDRL) test and a speciﬁc IgM (immunoglobulin M) capture enzyme-linked immunosor-
bent assay (ELISA; Pathozyme-IgM) was assessed by Cox regression analysis.
Results. Forty-two percent of primary syphilis patients had a negative VDRL test at their diagnosis. Three
months after treatment, 85%–100% of primary syphilis patients had reached the VDRL endpoint, compared with
76%–89% of patients with secondary syphilis and 44%–79% with latent syphilis. In the overall multivariate Cox
regression analysis, serological response to treatment was not inﬂuenced by human immunodeﬁciency virus (HIV)
infection and reinfection. However, within primary syphilis, HIV patients with a CD4 count of <500 cells/μL had
a slower treatment response (P = .012). Compared with primary syphilis, secondary and latent syphilis showed a
slower serological response of VDRL (P = .092 and P < .001) and Pathozyme-IgM tests (P < .001 and P = .012).
Conclusions. The VDRL should not be recommended as a screening test owing to lack of sensitivity. The
syphilis disease stage signiﬁcantly inﬂuences treatment response whereas HIV coinfection only within primary
syphilis has an impact. VDRL test titers should decline at least 4-fold within 3–6 months after therapy for
primary or secondary syphilis, and within 12–24 months for latent syphilis. IgM ELISA might be a supplement
for diagnosis and treatment monitoring.
With 12 million new cases a year worldwide, syphilis
remains a global problem. According to the World
Health Organization, >90% of cases occur in develop-
ing countries [1]. Rising incidence has been reported
in many European countries since the mid-1990s [2].
Similarly in the United States, a resurgence of syphilis
has been noted after a nadir in 2000 [3].
For laboratory diagnosis of syphilis and for monitor-
ing treatment response, serological testing is the most
important approach. In patients coinfected with human
immunodeﬁciency virus (HIV), atypical serological
courses have been reported. Although the clinically
deﬁned treatment response does not seem to be inﬂu-
enced by HIV coinfection, serologically deﬁned treat-
ment failure has been reported [4]. This might be a
consequence of slower Venereal Disease Laboratory Re-
search (VDRL) test seroreversion in HIV-infected indi-
viduals [5]. However, when reviewing previous studies
in this ﬁeld, no ﬁrm conclusion can be drawn regarding
whether HIV coinfection signiﬁcantly alters the treat-
ment response. This issue still is important to address,
as today most HIV-infected individuals are treated with
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highly active antiretroviral therapy and probably have a restored
immune system. It is likely that this changed the response to
syphilis treatment in HIV patients.
We aimed to compare the serological response to treatment
between the different stages of syphilis and to examine the in-
ﬂuence of HIV coinfection.
METHODS
Study Population
This study was approved by the ethics committee of Zurich,
Switzerland. Retrospectively, we analyzed data from all patients
with syphilis at the University Hospital Zurich and City Hospi-
tal Triemli who met the following criteria: (1) serological diag-
nosis of syphilis at the Department of Dermatology between
January 1999 and December 2008, (2) start of therapy within 2
weeks after diagnosis, (3) therapy with 1 or 3 doses of benza-
thine penicillin G (except for patients with tertiary syphilis), and
(4) ﬁrst serological follow-up performed 20–375 days after
therapy. Subjects who did not attend follow-up testing within
this time period were excluded. We also excluded individuals
who did not receive antibiotic treatment of syphilis and patients
with incomplete clinical data. Disease stage was classiﬁed on the
basis of clinical examination and patient history. Most classiﬁca-
tions were done at the time when patients visited the clinic, and
only a few were classiﬁed retrospectively based on the patient
chart. Patients were examined to ensure absence or presence of
lesions and were considered to have primary syphilis (ulcers at
anogenital or oropharyngeal sites and positive serology), second-
ary syphilis (mucocutaneous skin lesions typical for secondary
syphilis and positive serology with or without concomitant
ulcers), latent syphilis (no clinical signs of syphilis and positive
serology), or tertiary syphilis (combination of clinical and
serological ﬁndings as well as cerebrospinal ﬂuid analysis). In
patients with previous history of syphilis, a ≥4-fold increase
of VDRL titer was required to diagnose a new syphilis case.
Serological results of the ﬁrst visit and all follow-up serologies
up to 2 years after treatment were collected for 264 patients.
Serological Tests
The VDRL test (Dade Behring, Düdingen, Germany), an immu-
noglobulin M (IgM) capture enzyme-linked immunosorbent
assay (ELISA; Pathozyme Syphilis M Capture, Omega Diagnos-
tic, Alva, United Kingdom), and the Treponema pallidum parti-
cle agglutination test (TPPA; Fujirebio, Tokyo, Japan) were
performed on all sera. The Fluorescent Treponemal Antibody-
Absorption test (bioMérieux, Geneva, Switzerland) was per-
formed on 254 of 264 patients. All tests were done according to
manufacturers’ instructions. If a ﬁrst-visit serum was VDRL
nonreactive, the sample was tested up to a 1:64 dilution to avoid
false-negative results due to the prozone phenomenon.
Data Analysis
Therapy start date was deﬁned as baseline. For VDRL analysis,
subjects were included if they had a reactive VDRL (titer
≥1:2) at their ﬁrst visit (baseline) or within 4 weeks after base-
line. The endpoint was deﬁned as a 4-fold decrease in the
VDRL titer or reversion to nonreactive if the initial titer was
1:2 or 1:4. For Pathozyme-IgM analysis, individuals with a
baseline index of ≥0.9 were included. A drop of the Patho-
zyme-IgM index <0.9 was deﬁned as the endpoint.
Because patients had different follow-up time points, the
time of endpoint attainment had to be estimated. Logarithmic
curves were calculated for each patient, and the endpoint
times were calculated such that y = baseline VDRL/4 or y = 0
(for VDRL) or y < 0.9 (for IgM). If the calculated logarithmic
curve did not ﬁt the observed data (P > .1), the actual time to
the ﬁrst follow-up when VDRL was 4-fold decreased (or non-
reactive), or when IgM was <0.9, was used instead. Also, if the
endpoint was reached prior to the estimated time, the true
time was used. If the endpoint was not reached, the patient
was deﬁned as censored and the last follow-up was entered as
time variable.
For both VDRL and Pathozyme-IgM analyses, we calculated
a Cox regression to examine the overall effect on the serologi-
cal response to treatment of syphilis stage (except tertiary
syphilis, as there were too few patients in this group), HIV
coinfection according to the CD4 cell count, and reinfection.
Sex was excluded as it was not signiﬁcant in the univariate
analysis; therapy was excluded owing to colinearity problems
as it is dependent on the syphilis stage. In a second model, we
made Cox regression analyses for each syphilis stage (except
tertiary syphilis, as there were too few patients in this group)
to examine the effect of HIV coinfection and reinfection,
within a syphilis stage. All analyses were performed using
SPSS software, version 18 (IBM SPSS, Chicago, Illinois).
RESULTS
Clinical and Serological Baseline Characteristics
From January 1999 to December 2008, 456 patients were diag-
nosed with syphilis. A total of 192 patients were excluded (93
did not attend follow-up serological testing; 42 had incomplete
data about therapy or did not receive antibiotic treatment; 20
received nonstandard therapy; 24 started therapy >2 weeks
after diagnosis; and 13 had incomplete clinical data). Charac-
teristics of the remaining 264 patients are shown in Table 1
(see also Supplementary Table 1). Of the included patients,
92% were men, 42% were known to be HIV positive, and 13%
had a history of previous syphilis (ie, they were considered re-
infected). HIV coinfection was signiﬁcantly associated with
male sex (P = .001), hepatitis B infection (P = .031), history of
previous syphilis (P = .002), higher number of follow-up visits
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(P < .001), and longer (P < .001) mean duration of follow-up
(Table 1). HIV coinfection was also signiﬁcantly associated
with clinical stage of syphilis (P = .009); patients with
primary syphilis presented less frequently with HIV infection
than did patients with secondary or latent syphilis. Concern-
ing therapy, only 7 of 27 HIV patients with primary syphilis
received 1 dose of benzathine penicillin G, whereas 20 received
3 doses.
VDRL, Pathozyme-IgM, and TPPA baseline characteristics
are shown in Tables 2 and 3. Initial VDRL and TPPA titers
were signiﬁcantly lower (P < .001) and more often negative
(P < .001) in primary syphilis patients compared to those with
secondary, tertiary, or latent syphilis. Thirty-eight of 90 (42%),
0 of 133 (0%), 0 of 8 (0%), and 4 of 32 (12%) patients with
primary, secondary, tertiary, and latent syphilis, respectively,
had a negative VDRL test at their ﬁrst visit. Six of 90 (7%)
patients with primary syphilis had negative TPPA and VDRL
tests; the Pathozyme-IgM tests, however, were positive
(median index, 1.42 [range, 1.23–3.00]). Patients with tertiary
and latent syphilis showed a signiﬁcantly lower (P < .001)
Pathozyme-IgM baseline as compared to primary and second-
ary stage patients. Four of 90 (4%), 12 of 133 (9%), 3 of 8
(38%), and 7 of 33 (21%) patients with primary, secondary,
tertiary, and latent syphilis, respectively, had negative Patho-
zyme-IgM tests on the ﬁrst visit. Of the 4 patients with
primary-stage symptoms and negative IgM ELISA, 3 had a
history of previous syphilis. Across all stages of syphilis, 8 of
34 (24%) reinfected individuals showed a negative IgM test.
Serological Response to Treatment
For VDRL analysis, 214 subjects with an initially positive titer
were included. Based on Kaplan-Meier analysis, the median
Table 1. Characteristics of the Study Population, Overall and According to HIV Status
Characteristic HIV Positive (n = 112) HIV Negative (n = 152) Total (N = 264) P Value
Male sex 110 (98) 133 (88) 243 (92) .001a
Age, years, median (mean) 38 (38) 37 (39) 38 (38) NSb
Stage of syphilis .009c
Primary 27 (24) 63 (41) 90 (34)
Secondary 62 (55) 71 (47) 133 (50)
Tertiary 3 (3) 5 (3) 8 (3)
Latent 20 (18) 13 (9) 33 (13)
CD4 cell count, No.
>500 cells/µL 29 NA NA NA
200–500 cells/µL 68 NA NA NA
<200 cells/µL 3 NA NA NA
Unknown 12 NA NA NA
Coinfections
Hepatitis B virus infection 4 (4) 0 4 (2) .031a
Hepatitis C virus infection 4 (4) 1 (1) 5 (2) NSa
Gonorrhea 1 (1) 3 (2) 4 (2) NSa
Chlamydia 1 (1) 0 1 (0) NSa
History of syphilis 23 (21) 11 (7) 34 (13) .002a
Therapy <.001a
1 dose benzathine penicillin G, 2.4 mU i.m. 15 (13) 100 (66) 115 (44)
3 doses benzathine penicillin G, 2.4 mU i.m., 1-week intervals 94 (84) 47 (31) 141 (53)
Aqueous crystalline penicillin G, daily 6 × 3–4 mU i.v. for 10–14 days 3 (3) 5 (3) 8 (3)
No. of follow-up visits, mean 4.83 3.71 4.19 <.001d
Duration of follow-up, mean, days 460 347 395 <.001b
All data are No. (%) unless otherwise specified.
Abbreviations: HIV, human immunodeficiency virus; i.m., intramuscular; i.v., intravenous; NS, not significant; NA, not applicable.
a Fisher exact test.
b t test.
c Two-sided column proportions z test with significance level of .05 and Bonferroni correction. Patients with primary syphilis are significantly less often HIV-
positive than patients with secondary or latent syphilis.
d Exact Mann-Whitney test.
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Table 2. Serological Results at the Time of Diagnosis According to Clinical Stages of Syphilis
Baseline
Primary Syphilis
(n = 90)
Secondary Syphilis
(n = 133)a
Tertiary Syphilis
(n = 8)
Latent Syphilis
(n = 33)
Total
(N = 264) P Valueb
VDRL
Median titer 1:2 1:32 1:48 1:32 1:32 <.001
Interquartile range 1:0–1:16 1:32–1:64 1:16–1:128 1:4–1:64 1:4–1:64
Negative, No (%) 38 (42)c 0 0 4 (12)d 42 (16) <.001
TPPA
Median titer 1:640 1:20480 1:40960 1: 40960 1:10240 <.001
Interquartile range 1:160–1:3200 1:5120–1:81 920 1:20 480–1:266 240 1:5120–1:143 360 1:1280–1:40 960
Negative, No. (%) 6 (7)e 0 0 0 6 (2) .015
Pathozyme-IgM
Median titer 3.34 >3.50 2.00 1.39 >3.50 <.001
Interquartile range 1.78 to >3.50 2.47 to >3.50 <0.9 to >3.50 0.97–3.44 1.71 to >3.50
Negative, No. (%) 4 (4)f 12 (9)g 3 (38)h 7 (21)i 26 (10) .003
Abbreviations: HIV, human immunodeficiency virus; IgM, immunoglobulin M; TPPA,Treponema pallidum particle agglutination test; VDRL,Venereal Disease Research Laboratory test.
a In 1 patient, TPPA was not performed.
b Kruskal-Wallis test for median titers and Fisher exact test for number of negatives.
c Two of these 38 patients were reinfected and 9 were HIV infected (1 of whom had a reactive VDRL test 24 days after baseline). One also had a negative Pathozyme-IgM test.
d None of these 4 patients were reinfected and 3 were HIV infected. One also had a negative Pathozyme-IgM test.
e All 6 patients had a negative VDRL and a positive Pathozyme-IgM test. Two subjects were HIV infected.
f One patient was also negative for VDRL and none for TPPA. Three of these 4 patients were reinfected.
g Two of these 12 patients were reinfected and 7 were HIV infected.
h One of these 3 patients was reinfected and 2 were HIV infected.
i Two of these 7 patients were reinfected and 4 were HIV infected. One also had a negative VDRL test.
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time to endpoint (ie, a 4-fold drop of the titer or reversion to
nonreactive) was 37 days (95% conﬁdence interval [CI], 29–45
days) for primary, 49 days (95% CI, 46–52 days) for second-
ary, and 68 days (95% CI, 25–112 days) for latent syphilis.
The cumulative serological response to treatment is shown in
Table 4. For example, 3 months after treatment, 85%–100% of
patients with primary syphilis had reached the endpoint, as
compared to 76%–89% with secondary syphilis and 44%–79%
with latent syphilis. In the overall multivariate Cox regression
analysis, VDRL serological response to treatment was
inﬂuenced by syphilis stage but not by HIV infection and re-
infection (Table 5). Compared to primary syphilis, latent syph-
ilis showed a signiﬁcantly slower treatment response (hazard
ratio [HR], 0.34 [95% CI, .2–.57]) and secondary syphilis
showed a trend to a slower response (HR, 0.74 [95% CI, .53–
1.05]). In the second model, when Cox regression analyses
were performed for each syphilis stage, HIV-coinfected pa-
tients with primary syphilis and a CD4 count of <500 cells/µL
showed a signiﬁcantly slower treatment response compared
with HIV-negative patients (HR, 0.37 [95% CI, .17–.81];
Table 3. Serological Results at the Time of Diagnosis According to HIV Status
Baseline HIV Positive (n = 112) HIV Negative (n = 152) Total (N = 264) P Valuea
VDRL
Median titer 1:32 1:16 1:32 .001
Interquartile range 1:8–1:64 1:3–1:64 1:4–1:64
Negative, No. (%) 12 (11) 30 (20) 42 (16) NS
TPPA
Median titer 1:20 480 1: 5120 1:10 240 .002
Interquartile range 1: 2560–1:81 920 1: 640–1:40 960 1: 1280–1:40 960
Negative, No (%) 2 (2) 4 (3) 6 (2) NS
Pathozyme-IgM
Median titer 3.42 >3.50 >3.50 NS
Interquartile range 1.52 to >3.50 1.87 to >3.50 1.71 to >3.50
Negative, No. (%) 16 (14) 10 (7) 26 (10) NS
Abbreviations: IgM, immunoglobulin M; NS, not significant; TPPA, Treponema pallidum particle agglutination test; VDRL, Venereal Disease Research Laboratory
test.
a Mann-Whitney test for median titers and Fisher exact test for number of negatives.
Table 4. Serological Response to Treatment of Venereal Disease Research Laboratory and Pathozyme Immunoglobulin M According
to Clinical Stage of Syphilis and HIV Statusa
Baseline Primary Syphilis Secondary Syphilis Latent Syphilis HIV Uninfected HIV Infected
VDRL (n = 52) (n = 133) (n = 29) (n = 117) (n = 97)
At 90 days 92 (85–100) 83 (76–89) 62 (44–79) 86 (80–92) 77 (68–85)
At 180 days 100 99 (97–100) 76 (60–91) 96 (93–99) 94 (90–99)
At 270 days 100 100 83 (69–97) 98 (96–100) 97 (95–100)
At 360 days 100 100 93 (84–102) 98 (96–100) 100
At 540 days 100 100 93 (84–102) 98 (96–100) 100
Pathozyme-IgM n = 86 n = 121 n = 26 n = 138 n = 95
At 90 days 35 (24–45) 22 (14–29) 31 (13–49) 26 (19–33) 30 (21–39)
At 180 days 66 (55–76) 44 (35–54) 46 (27–66) 52 (43–61) 54 (43–64)
At 270 days 81 (72–90) 54 (45–64) 68 (48–87) 62 (53–71) 70 (60–80)
At 360 days 87 (79–95) 62 (52–72) 74 (54–94) 73 (64–81) 75 (66–85)
At 540 days 94 (87–101) 79 (69–90) 74 (54–94) 85 (75–95) 86 (77–95)
At 720 days 100 100 74 (54–94) 92 (82–103) 100
Patients with tertiary syphilis were excluded.
Abbreviations: HIV, human immunodeficiency virus; IgM, immunoglobulin M; VDRL, Venereal Disease Research Laboratory test.
a Data are estimated percentage of cases (estimated 95% confidence interval) based on Kaplan-Meier analysis.
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P = .012). There was no signiﬁcant inﬂuence of HIV coinfec-
tion in patients with secondary (P = .2) or latent (P = .41)
syphilis.
A total of 190 patients were followed for at least 1 year or
until they had seroreverted for the VDRL test (ie, had a non-
reactive VDRL test). Of these, 153 (81%) had seroreverted
within a year, 12 (6%) had seroreverted at their ﬁrst visit after
1 year, and 25 (14%) still had a positive VDRL after 1 year. Of
these 25, there were signiﬁcantly more reinfected patients
(28% as opposed to 10%, P = .022) and later stages of syphilis
(eg, latent or tertiary stage; 52% as opposed to 9%, P < .001),
when compared with the 153 patients with seroreversion (as
analyzed with Fisher 2-sided exact test; data not shown). None
of these 25 patients had evidence for insufﬁcient therapy. All
but 3 of these patients had initially high titers (≥1:16), which
decreased over time. Fourteen patients seroreverted during
further follow-up, the last seroreverting 4.2 years after treat-
ment. Compared to this, 11 patients maintained a positive
VDRL at the last follow-up, 1.1–3 years after treatment.
For the Pathozyme-IgM test analysis, 233 subjects with an
initial positive index were included. The median time to end-
point (ie, a drop below the cutoff index) was 130 days (95%
CI, 108–153 days) for primary, 245 days (95% CI, 138–352
days) for secondary, and 202 days (95% CI, 133–271 days) for
latent syphilis. One year after treatment, 13%, 38%, and 26%
of patients with primary, secondary, and latent syphilis, re-
spectively, did not reach the endpoint (Table 4). In the multi-
variate analyses, treatment response was not inﬂuenced by
HIV coinfection (P = .11 for those with a CD4 count of <500
cells/µL) or reinfection (P = .13), but by clinical stage. Patients
with secondary (HR, 0.53 [95% CI, .37–.76]) and latent (HR,
0.47 [95% CI, .26–.85]) syphilis showed a slower treatment re-
sponse compared to patients with primary syphilis (Table 5).
Also, in the second Cox regression analyses performed for
each syphilis stage, HIV coinfection had no effect on response
time (P value for HIV coinfection was .47, .2, and .27 in
primary, secondary, and latent syphilis, respectively).
DISCUSSION
Our study provides evidence that a combination of the TPPA
test and an IgM ELISA is superior to the VDRL test for diagno-
sis of syphilis. Furthermore, the syphilis disease stage signiﬁ-
cantly inﬂuences treatment response, whereas HIV coinfection
has an impact on the response only in primary syphilis.
Clinical and Serological Characteristics at Time of Diagnosis
We found a high rate of HIV and syphilis coinfection, which
is in agreement with other reports [6, 7]. This patient group
presented more often with latent or secondary syphilis, and a
substantial proportion were men who have sex with men, as
earlier described by the Swiss HIV Cohort Study [8].
As expected, we found signiﬁcantly lower VDRL and TPPA
titers in early stages of syphilis than in later stages. Interestingly,
38 of 90 patients presenting with primary syphilis symptoms
had a negative VDRL test result. In 37 of these patients, the
initially positive treponemal IgM declined after therapy, proving
that the VDRL result was false-negative. Thus, VDRL test
Table 5. Factors (Cox Regression Results) Determining Serological Response to Treatment for Venereal Disease Research Laboratorya
and Pathozyme-Immunoglobulin Mb
Factor
VDRL Pathozyme-IgM
Total (%) Hazard Ratio 95% CI P Value Total (%) Hazard Ratio 95% CI P Value
Syphilis stage
Primary 50 (24.4) 1 82 (36.4) 1
Secondary 127 (62.0) 0.747 .532–1.048 .092 117 (52.0) 0.531 .373–.757 <.001
Latent 28 (13.7) 0.338 .199–.573 <.001 26 (11.6) 0.469 .260–.846 .012
Reinfection
No 177 (86.3) 1 200 (88.9) 1
Yes 28 (13.7) 0.846 .538–1.331 .469 25 (11.1) 1.576 .879–2.826 .127
HIV status (CD4 cell count)
Negative 117 (57.1) 1 138 (61.3) 1
Positive (≥500 cells/μL) 25 (12.2) 1.266 .786–2.037 .332 27 (12.0) 1.029 .626–1.693 .910
Positive (<500 cells/μL) 63 (30.7) 0.825 .598–1.138 .241 60 (26.7) 1.373 .935–2.015 .106
Patients with tertiary syphilis were excluded.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IgM, immunoglobulin M; VDRL, Venereal Disease Research Laboratory test.
a For VDRL, n = 205 (51 missing).
b For Pathozyme-IgM, n = 225 (31 missing).
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sensitivity was only 58% for primary syphilis, which is lower than
previously reported sensitivities of between 66% and 87% [9–11].
Despite this, the VDRL test has been used for ﬁrst-line screening
in the United States [9], and is recommended in textbooks [12].
However, in recent years a paradigm shift is ongoing in the
UnitedStates towardusingsensitive andspeciﬁc enzyme immuno-
assays (EIAs) and chemiluminescence assays for screening [13].
In Europe, treponemal tests (EIA or TPPA), which have been
shown to be more sensitive, are recommended as single screening
tests [14].
In our laboratory, an IgM ELISA is performed for all sus-
pected primary syphilis cases in addition to the TPPA, our
standard screening test. The sensitivities of the TPPA and the
Pathozyme-IgM ELISA in primary syphilis were 93% and
96%, respectively. Six patients with negative TPPA and VDRL
yielded positive IgM ELISA results. The sensitivity when com-
bining TPPA with the IgM test was 100%. We therefore
suggest that in cases of suspected early infection, speciﬁc IgM
ELISA should be used in addition to other screening tests. It is
important that clinicians communicate the suspicion of an
early infection to the laboratory.
Serological Response to Treatment
As most of our HIV-infected patients probably had a restored
immune system, we would not expect to ﬁnd a signiﬁcant dif-
ference in regard to the serological response rate. Indeed, the
response rate of the VDRL test was high in both HIV-positive
and HIV-negative patients. In multivariate analyses, HIV co-
infection did not inﬂuence overall time to serological response
after treatment. However, when stratiﬁed by syphilis stage,
within primary syphilis, HIV-coinfected patients with low
CD4 cell count showed signiﬁcantly slower treatment respons-
es than HIV-negative patients. The majority of previous
studies, including several prospective [5, 10, 15–17] and retro-
spective studies [18–21], concluded that serologic failure or
time to serologic response of nontreponemal tests (ie, VDRL,
rapid plasma reagin) was not associated with HIV infection
even if analyses were stratiﬁed by syphilis stage [17, 19, 20].
Other studies, however, including one prospective trial [4],
found a signiﬁcant association [4, 22–24] or a trend [25]
between HIV status and response to treatment (ie, HIV-positive
patients had a higher risk for serofailure or a longer time to
serological response). Three of these studies also presented data
that were stratiﬁed by syphilis stage and demonstrated that,
compared with HIV-negative patients, HIV-positive patients
had (1) a higher risk for serofailure only if they had primary or
early syphilis [4, 22, 24], and (2) a slower response in latent
syphilis [22], or, conversely, slower response in primary syphilis
[4], which is in line with our results. Overall, there seems to be
a trend toward a slower response of nontreponemal tests in
HIV-coinfected patients. However, data in support of making a
clear distinction between HIV-positive and HIV-negative pa-
tients as recommended by the European guidelines for manage-
ment of syphilis are scarce [14].
We observed faster serological responses to treatment in
earlier stages of syphilis. One year after treatment, 7% (95%
CI, 0%–16%) of patients with latent syphilis still showed sero-
logical failure in the VDRL test. In multivariate analyses,
latent syphilis was a signiﬁcant predictor for a slower response
of the VDRL titer. Previous studies also reported slower re-
sponse rates in later stages of syphilis [17, 19, 22, 23, 26]. On
the basis of our observations, we would propose, similar to the
Centers for Disease Control and Prevention guidelines [27],
that nontreponemal test titers should decline 4-fold within 3–
6 months after therapy for primary or secondary syphilis, and
within 12–24 months for latent syphilis.
Of interest is our ﬁnding that 81% of patients had serore-
verted within a year after treatment, that is, the VDRL test
became nonreactive, which is higher than the previously re-
ported proportion of 13%–44% [5, 15, 26]. Almost half of the
remaining patients never seroreverted (ie, they had a positive
VDRL test at the last follow-up). We suggest, as previously re-
ported [5], that patients with persistently low VDRL titers
may be considered successfully treated.
The Pathozyme-IgM ELISA also proved reliable for moni-
toring the treatment response. However, the response rate was
markedly slower than that for the VDRL test. Previous studies
[28, 29] of another commercial IgM ELISA (Mercia IgM EIA)
reported negative test results 12 months after treatment in
92%–100% of patients presenting with early syphilis, com-
pared with 62%–87% in our study. A speciﬁc IgM ELISA
might be especially valuable for monitoring patients with an
initially negative VDRL test (mainly primary syphilis cases)
and in patients with a slow decline or persisting low VDRL
reactivity.
Our retrospective study has limitations: (1) A selection bias
is of concern because 42% of patients were excluded owing to
missing information on follow-up, treatment, or clinical data
or because they did not receive standard therapy. (2) Because
of the retrospective nature of the study, patients had different
follow-up time points. (3) A large number of cases of the
latent syphilis group involved patients with syphilis of
unknown duration (ie, it is not known whether they had early
or late latent syphilis). (4) It is difﬁcult to ascertain whether a
patient has experienced reinfection or relapse due to treatment
failure. However, we assume that at least 77% of these patients
had a reinfection as they had documented previous residual
antibodies or presented with a genital ulcer. (5) We cannot
ascertain that the patients did not use other antibiotics for
other reasons between follow-up visits. Finally, although this
is one of the largest studies in the ﬁeld, the small number of
events still impairs statistical power.
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CONCLUSIONS
For primary syphilis, the VDRL test should not be recommended
as ﬁrst-line screening test because of its lack of sensitivity. In con-
trast, both the TPPA test and IgM ELISA were sensitive and the
combined sensitivity reached 100%. HIV coinfection did not in-
ﬂuence the overall time to serological response to treatment in the
VDRL test. However, within primary syphilis, HIV patients with
a CD4 count of <500 cells/μL had a slower treatment response.
The clinical stage of syphilis had a signiﬁcant impact on the sero-
logical response; compared with primary stage syphilis, latent
stage syphilis showed a slower treatment response. Generally, the
VDRL titer should decline at least 4-fold within 3–6 months after
therapy for primary or secondary syphilis, and within 12–24
months after therapy for latent syphilis. Patients with persistently
low VDRL titers after treatment may be considered to be success-
fully treated. The Pathozyme-IgM ELISA proved to be a reliable
supplement for monitoring the treatment response.
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